Deals 2 July 2004
Middletons acted in the successful capital raising and ASX listing of the international biotechnology company CyGenics Ltd with a market capitalisation of just under $70 million on IPO.
Middletons acted in the successful capital raising and ASX listing of the international biotechnology company CyGenics Ltd with a market capitalisation of just under $70 million on IPO. CyGenics is a leader in the development and commercialisation of stem cell related technologies and applications covering tissue banking, tissue engineering, cell growth biomanufacturing, biologics and cell therapy. The fund raising through the IPO will provide for further business expansion and human clinical trials of the technology. Partners Peter Howard and Andrew Gaffney headed the Middletons team in the listing.
Skadden represented Gucci Group N.V. in the approximately US$3 ($4.3) billion acquisition by Pinault-Printemps-Redoute S.A. (PPR) of all of the outstanding common shares of Gucci not already owned by PPR. Under the terms of the transaction, PPR, Gucci’s majority shareholder, purchased the Gucci shares held by the public at a price of US$85.52 per share. PPR committed to make the offer in September 2001 in connection with the litigation settlement between Gucci, PPR and LVMH. Based in the Netherlands, Gucci Group is one of the world’s leading multi-brand luxury goods companies.